Skin Necrosis after High Dose Vasopressor Infusion in Septic Shock -Two Case Reports-

다국어 초록 (Multilingual Abstract)

Survival sepsis campaign recommends that vasopressor therapy is required to maintain mean arterial pressure (MAP) ≥ 65 mmHg. However, the absolute maximum dose of vasopressor is difficult to determine. Herein, we report 2 cases of severe skin necrosis after high dose vasopressor infusion to maintain the recommended MAP in septic shock. In our first case, norepinephrine 1.0－2.0 μg/kg/min and vasopressin 0.03－0.1 U/min were infused for 5 days; in the second case, dopamine 10－20 μg/kg/min and norepinephrine 0.25－2.5 μg/kg/min were infused for 7 days. Severe ischemic skin lesions, which required amputations, developed in both cases. The clinical appearance of the skin lesions in the 2 cases was different because of the unique distribution of target receptors for different vasopressors. Thus, when high dose vasopressors are required to achieve recommended MAP, extra vigilance is required. Further studies for dose adjustment are needed.

참고문헌 (Reference)

1 Hayes MA, "Symmetrical peripheral gangrene: association with noradrenaline administration" 18 : 433-436, 1992

2 Molos MA, "Symmetrical peripheral gangrene and disseminated intravascular coagulation" 121 : 1057-1061, 1985

3 Dellinger RP, "Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008" 34 : 17-60, 2008

4 Kahn JM, "Skin necrosis after extravasation of low-dose vasopressin administered for septic shock" 30 : 1899-1901, 2002

5 Rossi M, "Skin microcirculation in peripheral arterial obliterative disease" 58 : 427-431, 2004

6 Kingston ME, "Skin clues in the diagnosis of life-threatening infections" 8 : 1-11, 1986

7 Eun Hee Kim, "Skin Necrosis after a Low-Dose Vasopressin Infusion through a Central Venous Catheter for Treating Septic Shock" 대한내과학회 21 (21): 287-290, 2006

8 Holmes CL, "Physiology of vasopressin relevant to management of septic shock" 120 : 989-1002, 2001

9 Dünser MW, "Ischemic skin lesions as a complication of continuous vasopressin infusion in catecholamine-resistant vasodilatory shock: incidence and risk factors" 31 : 1394-1398, 2003

10 Donnellan F, "Ischaemic complications of Glypressin in liver disease: a case series" 64 : 550-552, 2007

11 Overgaard CB, "Inotropes and vasopressors: review of physiology and clinical use in cardiovascular disease" 118 : 1047-1056, 2008

12 Castellanos-Ortega A, "Impact of the Surviving Sepsis Campaign protocols on hospital length of stay and mortality in septic shock patients: results of a three-year follow-up quasi-experimental study" 38 : 1036-1043, 2010

13 Bonamigo RR, "Extensive skin necrosis following use of noradrenaline and dopamine" 21 : 565-566, 2007

14 Yefet E, "Extensive epidermal necrosis due to terlipressin" 13 : 180-181, 2011

15 Shiramizo SC, "Decreasing mortality in severe sepsis and septic shock patients by implementing a sepsis bundle in a hospital setting" 6 : e26790-, 2011